Under the strategic alliance, the companies expect to launch the product in the fourth quarter of 2010. IntelGenx will complete the development of the product, using its patented proprietary delivery technologies. IntelGenx will be entitled to fees for the development of the product as well as recurring revenue through a share of Dava’s US gross profit. Dava will be responsible for commercialization and marketing activities in the US.
IntelGenx now has nine products in development with its first product (pre-natal vitamin) to be commercialized in the second half of 2008. In addition, the company expects to engage in additional development and commercial alliances thereby expanding their product pipeline with new and existing partnerships in 2008.
Horst Zerbe, president and CEO of IntelGenx, said: “This alliance illustrates IntelGenx’s business strategy whereby we seek out key commercialization partners for development of products with significant potential using our drug delivery technologies.”